"Why are we accruing $2.3 million for a country where we've barely enrolled?"
Every Head of Clinical Finance has been on the call where that question gets asked usually by a CFO, usually three days before quarter close, and usually with no good answer in front of them. The accrual was built on a model. The model was built on enrollment assumptions from twelve weeks ago. The assumptions came out of CTMS, exported into a spreadsheet, summarized in a finance template, and posted into the books. Somewhere across those four steps, the truth drifted. By the time the CFO is asking, the gap is real, the period is closing, and the explanation is going to take a week of reconciliation that nobody has time for.
This is the operational reality inside most Biotech and mid-size CRO finance functions today. CTMS captures the visits, the milestones, the monitoring work the actual operational events that drive what should be paid and what should be accrued. But the financial work happens somewhere else. Budgets live in spreadsheets or a niche financial tool. Invoices and payments flow through ERP. Accruals get rebuilt at quarter-end from whatever data the FP&A analyst can pull together in time. Each system is doing its job. Together, they're producing two different financial truths about the same trial.
The drift doesn't start with bad data. It starts with the gap between when an operational event happens and when finance learns about it.
A treatment visit is completed at a German site on Tuesday. The site coordinator marks it complete in CTMS on Friday. The finance team accrues for it at month-end based on a percentage-of-completion estimate built from last month's enrollment forecast not from the visit itself. The site invoices for it six weeks later, after the contract's payment terms allow. The payment posts in a different period than the original accrual. By the time a CFO or an audit committee asks how much was actually spent on that site in Q3, the answer requires reconciling four systems that weren't designed to reconcile with each other.
The same drift makes site payment disputes structurally inevitable. A site coordinator emails the Project Manager: "we believe we're owed for visits 4 through 7 at three subjects but we haven't been paid." The PM doesn't have a single record to point to. They check CTMS visits look complete. They email finance finance shows a different visit count, because the accrual was built before the last two visits were entered. They check the contract the payment trigger language is ambiguous on whether one visit type qualifies. The dispute now requires three people, two days, and an email thread that nobody wants to be on. Multiply that by a hundred sites in a global program and you have a structural drag on site relationships that no amount of CRO management can fix.
The structural problem isn't that any individual system is failing. CTMS is doing exactly what it was built to do tracking visits, milestones, and monitoring activity. Finance is doing exactly what it was built to do recording payments and posting accruals. The problem is that the two systems are answering the same question what is this trial actually costing us right now? with two different sets of numbers, built from two different snapshots of reality, on two different timelines.
The reconciliation work between those two truths the spreadsheets, the quarter-end fire drills, the percentage-of-completion estimates that everyone knows are approximations is the hidden tax. It's paid by the FP&A team in late nights at quarter close. It's paid by the Project Manager in awkward emails to site coordinators. And it's paid, less visibly, by leadership in cash forecasts that don't quite match operational reality.
The fix isn't a better integration between CTMS and finance. The fix is eliminating the gap between them entirely.
When CTMS and Clinical Trial Financial Management run on the same Salesforce-native platform same data model, same record, same audit trail every operational event has a financial meaning the moment it happens. A visit completed in CTMS doesn't need to be exported, transformed, and reconciled into an accrual. The accrual is the visit. Rate cards, investigator grants, and milestone payment rules sit attached to the same study, country, and site records that Clinical Operations is already using. When a coordinator marks a visit complete, CTFM knows immediately whether that visit triggers an accrual, a payable, both, or neither based on the contract terms attached to that exact site.
Two things change for a Head of Clinical Finance the moment that architecture is in place.
Accruals become defensible. The number that posts to the financial statements at quarter-end traces back to a specific list of visits and milestones in CTMS. When the CFO asks why a country is accruing $2.3 million, the answer is a one-click drilldown to the underlying events — not a week of reconciliation. The same drilldown is available to the auditor. The accrual stops being an estimate the finance team has to defend and becomes a calculation the system can produce on demand.
Site payment disputes get resolved in minutes, not days. When a coordinator queries a payment, the PM and the finance lead are both looking at the same record. The visits that were recognized, the contract terms that triggered the payment, the date the payment was approved — all visible in one view. Most disputes evaporate the moment both sides are looking at the same data. The site relationship — which is one of the hardest things to repair once it cracks — stays intact.
In a Biotech operating on a defined runway, financial visibility into clinical operations isn't a finance department concern. It's a board concern. Cash forecasts that don't match operational reality are how funding rounds get built on numbers that no longer exist. Accruals that drift from actual spend are how quarterly results surprise the audit committee. Site payment disputes are how CROs and sponsors lose the trust of investigators who took years to recruit.
A unified Salesforce-native CTMS and CTFM platform one that treats every CTMS event as both an operational signal and a financial signal — gives finance and operations leaders a single version of the truth they're both working from. Not two reports that need reconciling. One record that everyone is looking at.
That's not a technology improvement. It's a control improvement. And in capital-constrained environments, control is the difference between a Biotech that can defend its numbers to a board and one that finds out about a problem when it's already too late to fix.
If your finance team is rebuilding accruals from CTMS exports every quarter and your Project Managers are still settling site payment disputes over email threads the gap isn't operational. It's architectural.
Schedule a 30-minute working session with a Cloudbyz Clinical Solutions lead.